Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHIDELTA PHARMA from Liège, company number BE0694733893, closed financial year 2025 with a result of € 38 after tax. For that financial year PHIDELTA PHARMA recorded a gross margin of € 119,730 and equity of € 53,943. Compared with financial year 2024, the result moved from € 359 to € 38. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 28, 2026.
€ 53,943
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 38
▼ 89% vs 2024
Profit after tax over the fiscal year.
€ 31,342
▼ 6% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 41,543.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 91,055
▼ 4% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 75,381
▲ 46% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 23,579
▼ 18% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 90,979 | € 106,315 | € 128,180 | € 119,730 | ▼ 7% |
| Profit after taxes | € 7,677 | € 15,570 | € 359 | € 38 | ▼ 89% |
| Equity | € 39,641 | € 53,545 | € 53,905 | € 53,943 | |
| Total debts | € 183,474 | € 156,021 | € 172,407 | € 162,393 | ▼ 6% |
| Cash | € 10,476 | € 16,292 | € 33,233 | € 31,342 | ▼ 6% |
| Retained profit | € 27,241 | € 41,145 | € 41,505 | € 41,543 | |
| Dividend | € 1,600 | € 1,666 | € 0 | € 0 | |
| Bank debt | € 24,898 | € 2,944 | € 593 | € 0 | ▼ 100% |
| Balance sheet total | € 223,115 | € 209,566 | € 226,312 | € 216,336 | ▼ 4% |
Key figures of PHIDELTA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHIDELTA PHARMA?
What happened at PHIDELTA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 38 (▼ 89% vs 2024). filed late Source: NBB ↗
- Maxine BAIVIER became a director. NBB
- Jamal AZROUR stepped down as director. NBB
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 7,677 profit in 2022 to € 38 profit in 2025.
Paid € 13,921 in corporate taxes since 2022.
Best year ever: 2023, with € 15,570 profit.
Paid out € 3,266 in dividends to the owners in total.
A new publication or filing at PHIDELTA PHARMA? We notify you, reason included.
Follow PHIDELTA PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHIDELTA PHARMA is Maxine BAIVIER.
Directors
According to the 2025 annual accounts
Maxine BAIVIER
Director
since 2026
Jamal AZROUR
Director
· until 2026
Establishments
Establishment units
Physical locations of this company
Rue Sainte-Marguerite 279
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0694.733.893
- VAT number
- BE 0694.733.893
- Registered office
- Rue Sainte-Marguerite 279, 4000 Liège
- Names & denominations
- PHIDELTA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 April 2018
- Peppol
- Active · Active since 4 Nov 2025
- Contact
- 042261451
- Activities · NACE
Detailhandel in farmaceutische producten